Sølling AS - Search Results

1

Romosozumab for the treatment of osteoporosis - a systematic review.

Mäkinen VN, Sølling AS, McClung M, Langdahl BL. Mäkinen VN, et al. Among authors: solling as. J Endocrinol Invest. 2024 Nov 2. doi: 10.1007/s40618-024-02469-1. Online ahead of print. J Endocrinol Invest. 2024. PMID: 39487940 Review.

2

Denosumab Discontinuation.

Sølling AS, Tsourdi E, Harsløf T, Langdahl BL. Sølling AS, et al. Curr Osteoporos Rep. 2023 Feb;21(1):95-103. doi: 10.1007/s11914-022-00771-6. Epub 2022 Dec 24. Curr Osteoporos Rep. 2023. PMID: 36564572 Review.

3

Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.

Sølling AS, Harsløf T, Jørgensen NR, Langdahl B. Sølling AS, et al. Osteoporos Int. 2023 Mar;34(3):599-605. doi: 10.1007/s00198-022-06651-0. Epub 2022 Dec 22. Osteoporos Int. 2023. PMID: 36543965 Clinical Trial.

4

Discontinuation of denosumab in men with prostate cancer.

Sølling AS, Harsløf T, Brockstedt HK, Langdahl B. Sølling AS, et al. Osteoporos Int. 2023 Feb;34(2):291-297. doi: 10.1007/s00198-022-06610-9. Epub 2022 Nov 19. Osteoporos Int. 2023. PMID: 36402867

5

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.

Sølling AS, Harsløf T, Langdahl B. Sølling AS, et al. J Bone Miner Res. 2021 Jul;36(7):1245-1254. doi: 10.1002/jbmr.4305. Epub 2021 Apr 20. J Bone Miner Res. 2021. PMID: 33813753 Free article. Clinical Trial.

6

The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA study.

Sølling AS, Harsløf T, Bruun NH, Langdahl B. Sølling AS, et al. Osteoporos Int. 2021 Aug;32(8):1557-1566. doi: 10.1007/s00198-021-05835-4. Epub 2021 Jan 30. Osteoporos Int. 2021. PMID: 33517477

7

Fracture rates in patients discontinuing alendronate treatment in real life: a population-based cohort study.

Sølling AS, Christensen DH, Darvalics B, Harsløf T, Thomsen RW, Langdahl B. Sølling AS, et al. Osteoporos Int. 2021 Jun;32(6):1103-1115. doi: 10.1007/s00198-020-05745-x. Epub 2021 Jan 7. Osteoporos Int. 2021. PMID: 33411002

8

Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial.

Sølling AS, Harsløf T, Langdahl B. Sølling AS, et al. J Bone Miner Res. 2020 Oct;35(10):1858-1870. doi: 10.1002/jbmr.4098. Epub 2020 Jul 12. J Bone Miner Res. 2020. PMID: 32459005 Free article. Clinical Trial.

9

Current Status of Bone-Forming Therapies for the Management of Osteoporosis.

Sølling ASK, Harsløf T, Langdahl B. Sølling ASK, et al. Drugs Aging. 2019 Jul;36(7):625-638. doi: 10.1007/s40266-019-00675-8. Drugs Aging. 2019. PMID: 31066015 Review.

10

The clinical potential of romosozumab for the prevention of fractures in postmenopausal women with osteoporosis.

Sølling ASK, Harsløf T, Langdahl B. Sølling ASK, et al. Ther Adv Musculoskelet Dis. 2018 Jun;10(5-6):105-115. doi: 10.1177/1759720X18775936. Epub 2018 Jun 7. Ther Adv Musculoskelet Dis. 2018. PMID: 29942362 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters